Paul Sandland

This profile gathers the share dealings of Paul Sandland in Dechra Pharmaceuticals PLC. In total, 9 filings cover trades dated from 16 September 2021 to 15 January 2024.

On the market, this insider has only ever bought: 4 purchases, €8,449 in total. The totals do not cover 3 filings with an undisclosed amount. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 5 share grants. Since January 2024: 4 purchases and no sales on the market.

On 4 out of 4 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster.

The latest filing, published on 15 January 2024, reports an open-market purchase of €8,449 in Dechra Pharmaceuticals PLC. The median gap between trade and publication is zero days: most filings appear on the same day. The regulation allows three business days to notify a trade (UK MAR). Every figure here comes from the filings published by RNS (LSE) and describes the past, not future prices; it is not investment advice.